> Skip repeated content

Comparing Tumor Necrosis Factor Inhibitors for RA and SpA: Overview & Expert Interview

Rheumatology Advisor—January 25, 2018

Rheumatology Advisor reporter Tori Rodriguez writes on tumor necrosis factor inhibitors (TNFis) in the fields of rheumatoid arthritis (RA) and spondyloarthritis (SpA).

She interviews Iris Navarro-Millan, MD, rheumatologist at HSS, who explains that there‚Äôs more data available on patients with RA than those with SpA. 

"It is important to take into consideration the reasons a patient needs to switch anti-TNFs. In patients whose reasons are related to side effects of the first anti-TNF drug, considering a second anti-TNF could be a reasonable approach. However, if the patient has not responded to an anti-TNF because of a lack of efficacy, given the broader treatment options available now, we have compelling data and treatment guidelines that support changing the mechanism of action of a biologic instead of using another that is in the same drug class," she says.

Read the full article at RheumatologyAdvisor.com.


Need Help Finding a Physician?

Call us toll-free at:

Media Contacts


Social Media Contacts